Please assess the completion status of the following clinical trial:

Trial Title: To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with overt signs of upper gastrointestinal bleeding (hematemesis, melena and/or circulatory instability)~* documented bleeding (Forrest I) from a non-variceal upper gastrointestinal source (gastro-duodenal ulcers, Mallory Weiss tear, cancers, Dieulafoy's and other vascular lesions) at endoscopy.~Exclusion Criteria:~* without a full informed consent from the patient or his next of kin~* Age \<18 years~* Pregnant~* Lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- TC-325 (Type: EXPERIMENTAL): Endoscopic Application of a Hemostatic Powder TC-325, \<=150gm , once
- standard treatment (Type: ACTIVE_COMPARATOR): standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine \<=20 clip or4 pulse , once only

Based on this trial design, predict the completion outcome and termination type (if applicable).